Latest news
Selection in the Best of the Liver Meeting 2021
ENYO Pharma has been highlighted in the “Best of The Liver Meeting 2021” for the oral presentation describing Vonafexor’s key effects after 12 weeks of treatment on liver and kidney functions in NASH patients, given by the LIVIFY Principal Investigator Pr Stephen Harrison during the Late Breaking Session 1 Sunday, November the 14th.
New collaboration with Dr David Durantel’s team
Following the positive proof-of-concept data from 203 study of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB), a new collaboration was initiated with the team of David Durantel at the International Center for Research in Infectiology (CIRI – INSERM U1111, https://ciri.ens-lyon.fr/teams/HepVir).
ENYO Pharma featured in Biomim’BOOK 2021
ENYO Pharma is featured in the 2021 edition of Biomim’BOOK, the first book dedicated to actors and stakeholders in Biomimetism and Bio-inspiration.
To see the full book: https://www.flickr.com/photos/biomimexpo/sets/72157718879047022/
To see ENYO Pharma double page: BIOMIM_BOOK 2021_ENYO PHARMA
Etienne Morel’s talk at the Virology Virtual Conference
Etienne Morel, collaborator of ENYO Pharma, gave a talk describing the results of our collaboration entitled “From virus-host molecular crosstalk to ER-mitochondria membrane interface mobilization in innate immunity” at the Virology Virtual Conference on March the 23th :
Conference description
New publication : Mitochondrial morphodynamics alteration induced by influenza virus infection as a new antiviral strategy
Together with the team of Etienne Morel, ENYO Pharma continues the antiviral exploration of its molecule targeting the NEET proteins, in the context of influenza virus. In this new article, we demonstrate that MITO-C exerts a membrane signature that strictly counteracts the signature applied by influenza virus infection on the mitochondria and on endoplasmic reticulum-mitochondria contact sites. Consequently, MITO-C potentiates Interferon expression and inhibits viral replication. Publication here